/KOD
KOD Stock - Kodiak Sciences Inc.
Healthcare|BiotechnologyNASDAQ
$26.00-1.44%
$0.38 (-1.44%) • Dec 19
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.12
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-34.6%upside
Target: $17.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KOD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.74 – $26.26
TARGET (TP)$17.00
STOP LOSS$23.92
RISK/REWARD1:-4.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.69
52W High$28.79
52W Low$1.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-26,706,000 | $-25,947,000 | $-11,001,000 | $-8,711,000 | $-4,208,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-186,849,000 | $-277,321,000 | $-341,379,000 | $-267,051,000 | $-136,007,000 |
| Net Income | $-176,207,000 | $-260,491,000 | $-333,823,000 | $-266,990,000 | $-133,096,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.35 | $-4.97 | $-6.39 | $-5.16 | $-2.91 |
Company Overview
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
25%
Hold / Neutral
7
58%
Sell / Underperform
2
17%
Analyst Consensus🔴 Bearish
3 Bullish9 Neutral/Bearish
Price Targets
$13
Average Target
↓ 48.8% Downside
Now
$2
Low
$13
Average
$24
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 11th 2025 | H.C. Wainwright | Upgrade | Buy | $24 |
| October 24th 2025 | JP Morgan | Upgrade | Overweight | $24 |
| September 25th 2025 | Barclays | Upgrade | Equal Weight | $17 |
| September 22nd 2025 | Jefferies | Initiation | Buy | $15 |
| August 14th 2025 | JP Morgan | Upgrade | Neutral | $15 |
| December 9th 2024 | Jefferies | Upgrade | Buy | $20 |
| September 5th 2024 | H.C. Wainwright | Initiation | Neutral | $3 |
| December 11th 2023 | Goldman | Resumed | Sell | $2 |
| November 17th 2023 | CapitalOne | Upgrade | Overweight | $12← $7 |
| July 27th 2023 | UBS | Downgrade | Neutral | $4← $15 |
| July 25th 2023 | Chardan Capital Markets | Downgrade | Neutral | - |
| July 25th 2023 | JP Morgan | Downgrade | Underweight | - |
| July 24th 2023 | Jefferies | Downgrade | Hold | - |
| July 24th 2023 | CapitalOne | Downgrade | Equal Weight | $7 |
| November 15th 2022 | CapitalOne | Initiation | Overweight | $24 |
Earnings History & Surprises
KODBeat Rate
42%
Last 19 quarters
Avg Surprise
-4.1%
EPS vs Estimate
Beats / Misses
8/11
Last 12 quarters
Latest EPS
$-1.16
Q4 2025
EPS Surprise History
Q1 24
-31.4%
$-1.13vs$-0.86
Q2 24
+24.8%
$-0.82vs$-1.09
Q3 24
+1.1%
$-0.86vs$-0.87
Q4 24
+6.7%
$-0.84vs$-0.90
Q1 25
+6.7%
$-0.84vs$-0.90
Q2 25
-22.5%
$-1.09vs$-0.89
Q3 25
-2.0%
$-1.03vs$-1.01
Q4 25
-8.4%
$-1.16vs$-1.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-1.08 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.07 | $-1.16 | -8.4% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.01 | $-1.03 | -2.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.89 | $-1.09 | -22.5% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.90 | $-0.84 | +6.7% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.90 | $-0.84 | +6.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.87 | $-0.86 | +1.1% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-1.09 | $-0.82 | +24.8% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.86 | $-1.13 | -31.4% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-1.41 | $-0.95 | +32.6% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.23 | $-1.53 | -24.4% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-1.28 | $-1.35 | -5.5% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-1.58 | $-1.35 | +14.6% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.82 | $-1.47 | +19.2% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.77 | $-1.74 | +1.7% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-1.39 | $-1.83 | -31.7% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.29 | $-1.79 | -38.8% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-1.16 | $-1.30 | -12.1% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-1.04 | $-1.08 | -3.8% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.94 | $-0.98 | -4.3% | ✗ MISS |
Latest News
Kodiak Sciences shares are trading higher after the company anounced the pricing of a $160 million public offering of common stock at $23.00 per share.
➖ NeutralBenzinga•Dec 17, 2025, 04:20 PM
Reported Earlier, Kodiak Sciences Prices Upsized Public Offering Of Common Stock At $23.00 Per Share Raising Approximately $160M
📉 NegativeBenzinga•Dec 17, 2025, 06:23 AM
Kodiak Sciences shares are trading lower after the company announced a proposed public offering of 6 million shares.
📉 NegativeBenzinga•Dec 15, 2025, 09:05 PM
Kodiak Sciences Announces Proposed Public Offering Of 6M Share Common Stock
📉 NegativeBenzinga•Dec 15, 2025, 09:01 PM
Chardan Capital Maintains Neutral on Kodiak Sciences, Maintains $14 Price Target
➖ NeutralBenzinga•Nov 17, 2025, 12:14 PM
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $26
📈 PositiveBenzinga•Nov 17, 2025, 11:53 AM
Kodiak Sciences Q3 EPS $(1.16) Misses $(1.03) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:29 PM
HC Wainwright & Co. Upgrades Kodiak Sciences to Buy, Raises Price Target to $24
📈 PositiveBenzinga•Nov 11, 2025, 12:39 PM
Kodiak Sciences Announces Data From APEX Trial Of KSI-101 In Patients With Macular Edema Secondary To Inflammation
➖ NeutralBenzinga•Nov 5, 2025, 12:27 PM
Kodiak spikes as J.P. Morgan upgrades on eye disease drug, KSI-101
📈 PositiveSeeking Alpha•Oct 24, 2025, 01:16 PM•Also:
JP Morgan Upgrades Kodiak Sciences to Overweight, Raises Price Target to $24
📈 PositiveBenzinga•Oct 24, 2025, 10:30 AM•Also:
Kodiak Sciences shares are trading higher after Barclays upgraded the stock from Underweight to Equal-Weight and raised its price target from $7 to $17.
📈 PositiveBenzinga•Sep 25, 2025, 03:46 PM•Also:
Barclays Upgrades Kodiak Sciences to Equal-Weight, Raises Price Target to $17
📈 PositiveBenzinga•Sep 25, 2025, 11:11 AM•Also:
Kodiak Sciences shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $15 price target.
📈 PositiveBenzinga•Sep 22, 2025, 03:25 PM
Jefferies Initiates Coverage On Kodiak Sciences with Buy Rating, Announces Price Target of $15
📈 PositiveBenzinga•Sep 22, 2025, 03:04 PM
Kodiak Sciences Highlights Phase 1b Results As KSI-101 Delivers Rapid Retinal Drying And Clinically Meaningful Vision Improvement
📈 PositiveBenzinga•Sep 15, 2025, 11:13 AM
HC Wainwright & Co. Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
➖ NeutralBenzinga•Aug 18, 2025, 10:37 AM
Kodiak Sciences Beats Q2 Loss Estimates
📈 PositiveThe Motley Fool•Aug 13, 2025, 08:13 PM
Frequently Asked Questions about KOD
What is KOD's current stock price?
Kodiak Sciences Inc. (KOD) is currently trading at $26.00 per share. The stock has moved -1.44% today.
What is the analyst price target for KOD?
The average analyst price target for KOD is $17.00, based on 1 analyst.
What sector is Kodiak Sciences Inc. in?
Kodiak Sciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KOD's market cap?
Kodiak Sciences Inc. has a market capitalization of $1.38 billion, making it a small-cap company.
Does KOD pay dividends?
No, Kodiak Sciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to KOD for comparison